Kopelman, Jared
Keller, Timothy A.
Panny, Benjamin
Griffo, Angela
Degutis, Michelle
Spotts, Crystal
Cruz, Nicolas
Bell, Elizabeth
Do-Nguyen, Kevin
Wallace, Meredith L.
Mathew, Sanjay J. http://orcid.org/0000-0002-2715-6641
Howland, Robert H.
Price, Rebecca B. http://orcid.org/0000-0002-7590-4325
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH113857)
Article History
Received: 25 March 2023
Revised: 17 April 2023
Accepted: 25 April 2023
First Online: 9 May 2023
Competing interests
: RBP is the named inventor on a University of Pittsburgh-owned patent filing related to a novel combination intervention tested in this clinical trial. SJM is supported through the use of facilities and resources at the Michael E. DeBakey VA Medical Center, Houston, Texas, and receives support from The Menninger Clinic. SJM has served as a consultant to Alkermes, Allergan, Axsome Therapeutics, BioXcel Therapeutics, Clexio Biosciences, Eleusis, EMA Wellness, Engrail Therapeutics, Greenwich Biosciences, Intra-Cellular Therapies, Janssen, Levo Therapeutics, Neurocrine, Perception Neuroscience, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Sunovion, and Signant Health. He has received research support from Biohaven Pharmaceuticals, Merck, Neurocrine, Sage Therapeutics, and VistaGen Therapeutics. All other authors report no financial conflicts of interest to disclose.